ag 1879 has been researched along with gemcitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashley, SW; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 1 |
| Ichihara, N; Kitanaka, A; Kubota, Y; Taminato, T; Tanaka, T | 1 |
2 other study(ies) available for ag 1879 and gemcitabine
| Article | Year |
|---|---|
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Ribonucleoside Diphosphate Reductase; src-Family Kinases; Transcription Factors; Tyrosine | 2004 |
Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Serum; Signal Transduction; src-Family Kinases; Transfection | 2008 |